MetaCap

Altimmune (ALT) vs Relmada Therapeutics (RLMD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Relmada Therapeutics (RLMD) has outperformed Altimmune (ALT) over the past year, losing 38.6% versus a loss of 72.3%. Over five years, RLMD leads with a -86.1% price change compared with -87.2% for ALT. Relmada Therapeutics is the larger company by market cap ($279.5 million vs $258.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALT-72.35%RLMD-38.64%
+92%+6%-80%
Nov 21, 20251 yearNov 20, 2026
ALT-87.39%RLMD-87.15%
+123%+7%-109%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALT versus RLMD key metrics
MetricALTRLMD
Share price$1.33$2.62
Market cap$258.80M$279.54M
1-day change-5.67%-15.76%
YTD return-63.16%-45.76%
1-year return-72.35%-38.64%
5-year return-87.24%-86.09%
EPS (TTM)$-0.71$-0.73
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$41.00K—
Revenue growth (YoY)+105.00%—
Net income (latest FY)$-88.09M$-57.39M
Operating margin-230460.98%—
Net margin-214860.98%—
52-week high$6.44$8.00
52-week low$1.32$2.60
Distance from 52-week high-79.35%-67.25%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1127.82%+310.31%
Average volume3.91M1.45M
Shares outstanding194.59M106.69M
Employees5717
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RLMD has outperformed ALT by 33.7 percentage points over the past year.

About Altimmune

ALT stock →

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees

About Relmada Therapeutics

RLMD stock →

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

ALT vs RLMD FAQ

Which is bigger, Altimmune or Relmada Therapeutics?

Relmada Therapeutics (RLMD) is larger, with a market capitalization of $279.54M compared with $258.80M for Altimmune (ALT).

Which stock has performed better over the past year, ALT or RLMD?

RLMD returned -38.64% over the past 12 months, compared with -72.35% for ALT (price return, excluding dividends). Past performance does not predict future results.

Are Altimmune and Relmada Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons